# Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept

-A Panel Discussion

Stanley C. McDermott, PharmD, MS, RPh Managing Director – Regulatory Sciences Head, Clinical Research / Clinical Affairs Cardinal Health Regulatory Sciences



© Copyright 2015, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.

## **Session Objectives**

- Biopharmaceutical product development is a complex process, requiring extensive time and resources from sponsors and investors.
- Key concepts to consider during the development and approval processes for new drugs;
  - emphasis on how inventors and entrepreneurs can minimize the time to confirm clinical proof of concept (PoC)
- Better understanding of how to simplify this highly interesting, yet complicated process.




# **Expertise and credentials**

- Industry- and FDA-trained experts providing regulatory science and product development consulting services required for product approval and product lifecycle management
- 120+ NDA/BLA/ANDA approvals supported
- **500+** INDs supported
- **500+** approved products under maintenance (100+ countries)






## **Core service areas**





#### New Drug and Biologics Approvals and Research and Development Spending




Joseph A. DiMasi. Cost of Developing a New Drug [Briefing]. Tufts University Center for Drug Development. Nov 18, 2014. <u>http://csdd.tufts.edu/files/uploads/Tufts\_CSDD\_briefing\_on\_RD\_cost\_study\_-\_Nov\_18, 2014..pdf</u>, http://csdd.tufts.edu/news/complete\_story/cost\_study\_press\_event\_webcast



© Copyright 2015, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.

## **The New Drug Development Process**



http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm053131.htm




© Copyright 2015, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.

# Target selection & validation

#### Discovery

## **Development**





## **Target Selection & Validation**

- Define the unmet medical need (disease)
- Understand the molecular mechanism of the disease
- Identify a therapeutic target in that pathway (e.g. gene, key enzyme, receptor, ion-channel, nuclear receptor)
- Demonstrate that target is relevant to disease mechanism using genetics, animal models, lead compounds, antibodies, RNAi, etc.



## **Discovery through Nonclinical Development**

Develop an assay to evaluate activity of compounds on the target

- *in vitro* (e.g. enzyme assay)
- in vivo (animal model or pharmacodynamic assay)
- Identify a lead compound
  - screen collection of compounds ("compound library")
  - compound from published literature
  - screen Natural Products
  - structure-based design ("rational drug design")
- Optimize to give a "proof-of-concept" molecule—one that shows efficacy in an animal disease model
- Optimize to give drug-like properties—pharmacokinetics, metabolism, off-target activities
- Safety assessment, Preclinical Candidate!!!




## **Drug Product Design**

- Selection Criteria for Dosage Forms
  - Clinical Needs
  - Dose/Onset/Duration of Action
  - Product Performance
  - Patient Compliance/Acceptance
  - Marketing Considerations



#### **Discovery to Nonclinical - Convergence of Disciplines**



© Copyright 2015, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.

Essential to care"

## **Clinical Development**

- Submit Investigational New Drug (IND) Application
  - Provides exemption from a federal statute
  - Effective in 30 days if FDA does not object or request additional information
- Phase 1 Clinical Trials
  - Approximately 1 year in duration
  - Requires 20 to 80 subjects
  - Assess the safety profile, pharmacokinetic (PK) characteristics, and safe dosage range (SAD, MAD, MTD studies)\*
  - Evaluate absorption, distribution, metabolism and excretion (ADME studies), and the duration of presence/action

\*Single ascending dose (SAD), Multiple ascending dose (MAD), Maximum tolerated dose (MTD)

Modified based on information obtained from: www.fda.gov



## **Clinical Development**

- Phase 2 Clinical Trials
  - Approximately 2 years in duration
  - Controlled studies composed of 100 to 300 patients
  - Dose ranging in the target patient population
  - Assess safety and efficacy of dosing and formulation variances
- Phase 3 Clinical Trials
  - Approximately 3 years in duration
  - Requires 300 to 3,000 or more patients (intended use population)
  - Compare new therapies with existing standard of care and assess safety and efficacy of final (commercial) formulation product

Modified based on information obtained from: www.fda.gov



## **Developmental Clinical Pharmacology:** Emphasis on PoC

- Typically short, involving relatively few HVs/patients
  - FIH (SAD/MAD; with one patient cohort)
  - Phase 1 Biomarker
  - PK/PD
- Intelligent Go/No-Go endpoints
  - Proof of Mechanism
  - Proof of Efficacy
- Generally lack statistical significance
- High quality read-outs (PD, biomarker, etc..)
  - Clinical physiology
  - Adaptive designs



#### **Discussion**



© Copyright 2015, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.